Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jiro Okami, MD, PhD"'
Autor:
Ryu Kanzaki, MD, PhD, Hirokazu Watari, MD, Akiisa Omura, MD, Sachi Kawagishi, MD, Ryo Tanaka, MD, Tomohiro Maniwa, MD, Makoto Fujii, PhD, Jiro Okami, MD, PhD
Publikováno v:
Annals of Thoracic Surgery Short Reports, Vol 2, Iss 3, Pp 448-452 (2024)
Background: The significance of pulmonary artery (PA) diameter in patients with non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) who undergo pulmonary resection has not been elucidated. Methods: Data of 357 patients
Externí odkaz:
https://doaj.org/article/b411616eb370411bb774e4cc2f8850b6
Autor:
Kei Kunimasa, MD, PhD, Tomohiro Maniwa, MD, PhD, Motohiro Tamiya, MD, Takako Inoue, MD, Takahisa Kawamura, MD, PhD, Jiro Okami, MD, PhD, Kazumi Nishino, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100380- (2022)
Immunochemotherapy is widely used as the primary treatment for advanced lung cancer and is currently being investigated in the perioperative setting. Immunochemotherapy can produce marked tumor shrinkage and long-term anticancer effects that are not
Externí odkaz:
https://doaj.org/article/af29d31283dd4fed9d90dbb7726610e0
Autor:
Kei Kunimasa, MD, PhD, Yosuke Hirotsu, PhD, Kenji Amemiya, MSH, Harumi Nakamura, MD, PhD, Kazumi Nishino, MD, PhD, Keiichiro Honma, MD, PhD, Jiro Okami, MD, PhD, Masao Omata, MD, PhD, Toru Kumagai, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100305- (2022)
SCLC transformation in EGFR-mutated lung adenocarcinoma is one of the major phenotypic changes that is observed during the resistance to EGFR tyrosine kinase inhibitors. However, the mechanism of this transformation remains unclear. In this study, we
Externí odkaz:
https://doaj.org/article/28f84f778f764a779dbbe2d0cf8ba522
Autor:
Kei Kunimasa, MD, PhD, Jiro Okami, MD, PhD, Satoshi Takenaka, MD, PhD, Keiichiro Honma, MD, PhD, Yoji Kukita, PhD, Shigenori Nagata, MD, PhD, Takahisa Kawamura, MD, PhD, Takako Inoue, MD, Motohiro Tamiya, MD, Hanako Kuhara, MD, PhD, Kazumi Nishino, MD, PhD, Hideaki Tahara, MD, PhD, Toru Kumagai, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100235- (2021)
A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with verte
Externí odkaz:
https://doaj.org/article/6fce6fc2448440c289bbd4912081d54c